Cassava Sciences Shares Are Trading Lower After the Company Announced Simufilam Did Not Show a Significant Reduction in Cognitive or Functional Decline Versus Placebo in Patients With Mild-to-moderate Alzheimer's Disease in the ReThink-ALZ Phase 3 Study.
Cassava Sciences Shares Are Trading Lower After the Company Announced Simufilam Did Not Show a Significant Reduction in Cognitive or Functional Decline Versus Placebo in Patients With Mild-to-moderate Alzheimer's Disease in the ReThink-ALZ Phase 3 Study.
Cassava Sciences股票下跌，因公司宣佈Simufilam在ReThink-ALZ第3期研究中未顯示出在輕至中度阿爾茨海默病患者中相對安慰劑有顯著認知或功能衰退減少。
Cassava Sciences Shares Are Trading Lower After the Company Announced Simufilam Did Not Show a Significant Reduction in Cognitive or Functional Decline Versus Placebo in Patients With Mild-to-moderate Alzheimer's Disease in the ReThink-ALZ Phase 3 Study.
Cassava Sciences股票下跌，因公司宣佈Simufilam在ReThink-ALZ第3期研究中未顯示出在輕至中度阿爾茨海默病患者中相對安慰劑有顯著認知或功能衰退減少。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間